The advertisements below were submitted by prospective candidates and employers in the AACR Employment Register by January 10, 1994, and were updated as of June 15, 1994. Employers participating in the Employment Register may obtain information on the candidates in these advertisements and participating candidates may obtain information on positions in these advertisements by submitting written requests to the AACR Employment Register, Public Ledger Building, 620 Chestnut St., Suite 816, Philadelphia, PA 19106-3483. The request should give the identification number(s) appearing in the upper left-hand corner of the desired advertisement(s) and should include the registrant's own identification number or a completed employment register form with the appropriate fee attached. Forms were sent to all members of the AACR in the fall of 1993. They were also printed in the First Announcement of the Annual Meeting and in the December 1 (1993), December 15 (1993), January 1 (1994), and January 15 (1994) issues of Cancer Research.

Advertisements from all current participants in the Employment Register will also appear in the September 1 and November 1, 1994 issues of Cancer Research.

### POSITION LISTINGS

**201P** To study the regulation of hepatocyte growth as related to liver regeneration and multistage chemi-
carcinogenesis of liver. Conduct independent research on the expression/activation of oncogene
related tumor suppressor genes (p53, RB), and growth factors (HGF, TGFβ) and their receptors. Ex-
perience in biochemistry, molecular or cellular biol-
gy desired. Avail. Now. Salary, Neg. Contact: Dr. Randy L. Jirtle, Ph.D., Radiation Oncology, Box
343436, Duke University Medical Center, Durham NC
27710, (919)684-2770.

**202P** Postdoctoral in Cell and Molecular Biology. Conduct research on the identification and charac-
terization of genes involved in immortalization and trans-
formation of mammary epithelial cells in a super-
Contact: Dr. Kathleen M. Satterfield, Dept. of Cell Biology, University of Texas Health Science
Center at Houston, MD Anderson Cancer Center, Houston, TX 77030.

**203P** Res. Assoc. in Mol. Biol. to study regulation of expression of brain tumor antigens. Program
aimed at development of gene-based therapy (ret-
roviral vector mediated gene transfer; antisense; re-
lated). Salary dependent upon experience (25-40,000 range; negotiable). Contact Dr. J. R. Moskal, CINN, 426 W. Deming Pl., Chicago, IL 60614.

**204P** Postdoctoral Fellowships in Cancer Re-
search. Excellent investigators in basic research in tumor virology, molecular carcinogenesis, molecular therapeutics, molecular epidemiology, genetics, and tumor
immunology. Training is available in recombi-
nant DNA technology, gene expression, DNA repi-
cation, mutagenesis, regulation of cellular prolif-
eration, growth factors, molecular immunology, molecular genetics of cancer, and combined pro-
Dr. Joseph S. Pagano, UNC Lineberger Comprehensive
Cancer Center, Chapel Hill, NC.

**205P** Position available for the development of re-
search into the molecular mechanisms which govern regulation of proliferation in leukemia and normal hematopoietic cells. This information is being ap-
plied to the development of molecular and genetic therapy of leukemia. Immediate availability.
$40,000-$45,000. Contact: Dr. A. Deisseroth, Dept. of Hematology, MD Anderson Cancer Center, Hous-
ton, Texas.

**206P** Molecular cloning techniques are being used to dissect the positive and negative growth regula-
tory pathways which are operative in normal and leukemic hematopoietic cells. The focus is on in-
tracellular & cytoplasmic & cytoplasmic regulatory proteins which are involved in regulating prolifera-
tion in myeloid cells: RB, P53, RAF, GMCSF and interferon receptors and surface cytokinesis mol-
ecules. Immediate availability. $22,000-$26,000.
Contact: Dr. I. Deisseroth, Dept. of Hematology, MD
Anderson Cancer Center, Houston, TX.

**207P** Postdoctoral position for recent Ph.D. in bio-
molecular biology/biochemistry/molecular biology to investigate genetic engineering of MoAb's for hu-
1994. $27,000 to $36,000 depending on experience. Con-
tact Dr. Naik-Vong, C. Cheung, Department of Pedi-
atrics, Memorial Sloan-Kettering Cancer Ctr., NYC, NY
10021, 212-639-8401.

**209P** Postdoctoral in Carcinogenesis/Molecular or
Cellular Biology. Conduct research on role of protein
Kinases in a specific cell line. Experience in cell growth
and regulation. Available Sept. 1994. $25,000. Contact:
Frank L. Meyers, Jr., M.D., UCI Clinical Cancer Center, 101 City Drive, S., Orange, CA 92668.

**210P** Postdoctoral research position for Ph.D. in bio-
chemistry, molecular biology, pharmacology or related
field to study either polyamine metabolism or DNA
repair. Studies on the role of ornithine decar-
boxylase in cell transformation and repair of alky-
latants in resistant cell lines. Available
May 1994. $23,000-$27,000. Contact Dr. A. E.
College of Medicine, Hershey, PA 17033.

**211P** Postdoctoral positions (M.D./Ph.D.-US citi-
zen/resident available) in: Gene therapy for cancer &
gene transfer technology; T-cell apoptosis and acti-
vation; Perforin knockout—effects on immune re-
sponses. Funded by Training grant/individual grants;
training in molecular or cellular biology. Available
immediately: $19,000-$25,000. Dr. E.R. Pro-
deck, Dept. of Immunology, Univ. Miami Schl Med, POB
0161, 1120 SW 8th Ave, Miami, FL 33136.

**212P** Director molecular oncology gene insertion
program. Rank/salary per experience. Limited
training. Substantial support and local support.
Available July 1, 1994. Contact Dr. Robert M. Kile-
gram, Dept. of Pediatrics, Medical College of Wis-
consin, 8701 Watertown Plank Rd., Milwaukee,
WI 53226; (414) 266-4110. Equal Opportunity Affirma-
tive Action Employer M/F/D.

**213P** Asst. to Assoc. Res. Prof. in genetic or mo-
lecular epidemiology to conduct independent & mul-
idisciplinary laboratory based research within a highly interactive Cancer Prev. & Control Prog at
the AZ Cancer Ctr. Extremely limited graduate teaching
required. Avail. July 1994. $50,000 to $60,000. Con-
tact: David S. Alberts, M.D., AZ Cancer Ctr, Univ. of
AZ, 1515 E. University Blvd, Tucson, AZ 85724. The
Univ. of AZ is an Equal Opportunity/Affirmative Ac-
tion Employer. Women & Minorities are urged to apply.

**214P** Clinical Pharmacologist/Medical Oncologist,
M.D., Ph.D. or M.D./Ph.D. primarily devoted to the
design and pharmacokinetic monitoring of clinical
research trials. Send C.V. to William H. Halt, M.D., Ph.
D., The Cancer Institute of New Jersey, 303
George Street, Suite 501, New Brunswick, NJ
08901.

**215P** Medical Oncologist, Assoc/Assoc Prof level,
M.D. or M.D./Ph.D. primarily devoted to laboratory research in the areas of molecular biology, immu-
nology or pharmacology. Send C.V. to William N.
Halt, M.D., Ph.D., The Cancer Institute of New
Jersey, 303 George Street, Suite 501, New Brunswick,
NJ 08901.

**216P** Medical Oncologist, Assoc/Assoc Prof level,
M.D. or M.D./Ph.D. primarily devoted to clinical re-
search. The ind'l should have exp. in the design and
conduct of clinical trials. Send C.V. to William N.
Halt, M.D., Ph.D., The Cancer Institute of New Jer-
sy, 303 George Street, Suite 501, New Brunswick,
NJ 08901.

**217P** Highly qualified Cancer Clinicians and Re-
searchers who have completed a residency in Inter-
national Medicine will be eligible for this guaranteed 2
year position. Applications will be reviewed by the
search committee comprised of members with 10
years of clinical experience followed by a year devoted
to formal training in basic and clinical research. Send
C.V. to William N. Halt, M.D., Ph.D., The Cancer
Institute of New Jersey, 303 George Street, Suite
501, New Brunswick, NJ 08901.

**218P** Postdoctoral positions available. One posi-
tion involves cell culture and cellular/molecular phar-
macology to study drug-induced topoisomerase I
and II-mediated DNA damage. A second position
involves studies on the pharmacokinetics/pharma-
codynamics of novel anticancer drug delivery sys-
tems. Send curriculum vitae and names of three references to: Thomas G. Burke, Ph.D., The Ohio State University College of Pharmacy, 500 W. 12th Avenue, Columbus, OH 43210, FAX: 614-292-7766.

**219P** Postdoctoral research associate desired to
participate in studies examining the regulation of
drug-induced apoptosis in human leukemia cells by
oncogenes and PKC-related signal transduction
receptors. Prior experience in signal transduction
and cell death mechanisms is desirable. Position
available Spring, 1994; start date flexible.
Contact: Dr. Steven Grant, Division of Hematology/
Oncology, University of Washington School of Medi-
cine, Seattle, WA.

**220P** Postdoctoral position for Ph.D. in biochem-
pharmacology/related area with experience in molecular biology to study oncogenes, tumor suppressor

genes and cell-cycle regulatory genes in the cyto-

Food and Drug Administration. Interested candidates should send their curric-

09M0000000

**222P** Postdoctoral or Associate Scientist in tumor bi-
ology; mammalian models. Conduct research on struc-

ture and function of factors associated with tumor cell growth in relation to their growth factors in a

**223P** Research Scientist in Experimental Therape-
utics, Ph.D. with 1-3 yrs. of postdoctoral experi-

tance in two studies in combination chemotherapy, drug evaluation, and model development as related to cancer and other diseases. Avail-

3632
254P Postdoctoral Position—Cell Biologist: The Molecular Hematopoiesis Laboratory has an immediate opening for a cell biologist to study the role of hematopoietic factors in the regulation of cell proliferation in transgenic mice and in cultured marrow cells.
Contact: H.J. Lawrence, MD, VA Med Center (11111H), 4150 Clement, San Francisco, CA 94111.
255P Post-doc. Fellow in Pharmacology Dept. Candidate must have experience in tumor biology and standardize molecular assays for diagnosis and prognosis of cancer. Independent research program is encouraged in related field of interest desirable. Contact Dr. J. Galvin, Div. of Clinical Sciences, Wadsworth Center, NYS Dep't. of Health, Albany, NY 12201.
257P New faculty member with interest & expertise in BMT. Opportunity to develop an independent clinical or preclinical model for pediatric BMT. Interest in transplant for hematologic malignancies & acquired blood disorders, inherited diseases, and gene therapy is particularly desired. Board eligibility and experience in adult & pediatric BMT required. Salary negotiable. Johns Hopkins Univ. School of Medicine is an Equal Opportunity/Affirmative Action Employer. Contact Dr. Curt Cavin, P.O. Box 3242, Baltimore, MD 21229.
259P Post doc position to study the regulation of ornithine decarboxylase gene expression during epidermal tumor development. Approaches include reporter gene techniques, histochemical and morphologic analyses, and protein purification. Exp. in biology and cell culture preferred. Avail. immedi. Contact Dr. S.K. Gilmour, Lankenau Medical Res. Ctr., 100 Lancaster Ave., Wynnewood, PA 19096.
260P Postdoctoral Fellow in human carcinogene-
sis. Laboratory Research will focus on analysis of replication errors in specific human cancers, exp. colorectal, ovary, and endometrium. Genes whose expression is altered by replication errors will be identified. Available immedi. Contact Dr. T.G. O'Brien, Lankenau Med. Res. Ctr., Wynnewood, PA 19096.

270P Research Scientist/Human Cancer Immunol-
omy will develop cancer specific immunological as-
says, such as CTL assays, for use as a measure of biological response in immunotherapeutic clinical trials. Will perform in vivo analysis of CTL responses in tumor-bearing animals with various tumor cell lines and in vitro tumor and CTL cell lines for use in identifying and cloning CTL epitope genes. Requires Ph.D., plus 2–5 years of post doctoral experience and expertise in molecular biology, immunology or cell biology.
280P Research Scientist/Immunology will de-
develop an animal model to investigate the humoral response and T cell help (Th1/Th2) involved in immune response generated by retroviral vectors encoding HIV or other protein antigens. Requires Ph.D. and 2 years of post-doctoral experience.
281P Research Scientist/Animal Cancer Immunotherapy will use various in vivo animal models to study the efficacy of a drug in activating the immune system. Requires Ph.D. or Ph.D. equivalent, plus 2–5 years of post doctoral experience and expertise in molecular biology, cancer immunology or cell biology.
282P Research Scientist/Viral Therapeutics will re-
search and develop new therapeutic agents for cancer using animal models. Requires M.D. or Ph.D., plus 2–5 years of post doctoral experience, but not required. Conduct research on molecular aspects of the regulation of xenotransferase expression in normal and cancerous tissues. Emphasis is on the development of new therapeutic agents to be tested in cell culture and in vivo.
283P Research Scientist in Mammalian Cell Biology. Position focuses on research/development of cell culture and serenascence-related tech-
nologies as cancer therapeutic. Position available immediately. Salary $50K depending on experience. Contact Dr. Deborah Wil-
son, Laboratory Director, AGIS Pharmaceuticals, 1709 Dryden Rd., Suite 200, Houston, TX 77030; Fax: (281) 469-7220.
284P Post-doctoral position to study tumor cell motility and invasion and role of growth factors, adhesion receptors (integrins and cadherins), and tissue and signal transduction in breast cancer and squamous cell carcinoma. Experience in protein biochemistry, and/or mol. biological. Available 7/94. Contact: Dr. Randall Kramer, UCSF, Dept. Anatomy and Sio-

285P Research Scientist in Mammalian Cell Biology. Position focuses on research/development of cell culture and serenascence-related tech-
nologies as cancer therapeutic. Position available immediately. Salary $50K depending on experience. Contact Dr. Deborah Wil-
son, Laboratory Director, AGIS Pharmaceuticals, 1709 Dryden Rd., Suite 200, Houston, TX 77030; Fax: (281) 469-7220.
286P Research Scientist in Mammalian Cell Biology. Position focuses on research/development of cell culture and serenascence-related tech-
nologies as cancer therapeutic. Position available immediately. Salary $50K depending on experience. Contact Dr. Deborah Wil-
son, Laboratory Director, AGIS Pharmaceuticals, 1709 Dryden Rd., Suite 200, Houston, TX 77030; Fax: (281) 469-7220.
287P Post-doctoral position to study tumor cell motility and invasion and role of growth factors, adhesion receptors (integrins and cadherins), and tissue and signal transduction in breast cancer and squamous cell carcinoma. Experience in protein biochemistry, and/or mol. biological. Available 7/94. Contact: Dr. Randall Kramer, UCSF, Dept. Anatomy and Sio-

288P Research Scientist/Animal Cancer Immunotherapy will develop cancer specific immunological assays, such as CTL assays, for use as a measure of biological response in immunotherapeutic clinical trials. Will perform in vivo analysis of CTL responses in tumor-bearing animals with various tumor cell lines and in vitro tumor and CTL cell lines for use in identifying and cloning CTL epitope genes. Requires Ph.D., plus 2–5 years of post doctoral experience and expertise in molecular biology, immunology or cell biology.
289P Research Scientist/Immunology will deve-
develop an animal model to investigate the humoral response and T cell help (Th1/Th2) involved in immune response generated by retroviral vectors encoding HIV or other protein antigens. Requires Ph.D. and 2 years of post-doctoral experience.
290P Research Scientist/Animal Cancer Immunotherapy will use various in vivo animal models to study the efficacy of a drug in activating the immune system. Requires Ph.D. or Ph.D. equivalent, plus 2–5 years of post doctoral experience and expertise in molecular biology, cancer immunology or cell biology.
291P Research Scientist/Viral Therapeutics will re-
search and develop new therapeutic agents for cancer using animal models. Requires M.D. or Ph.D., plus 2–5 years of post doctoral experience, but not required. Conduct research on molecular aspects of the regulation of xenotransferase expression in normal and cancerous tissues. Emphasis is on the development of new therapeutic agents to be tested in cell culture and in vivo.
GROUP ON GROWTH INDUCED GENETIC CHANGES

CANDIDATE LISTINGS


3C Ph.D. Student (Expected graduation-06/94), B.S. (Pharm-1988) Multidisciplinary resistance, cell culture, in vitro & in vivo cytotoxicity studies, Pharmacology of anti-cancer drugs in vitro & in vivo; Fast computer skills, experience in computer applications, writing research papers, and on clinical research projects. Salary negotiable.


16C Ph.D., 1984, Microbiology; Pathogenesis of opportunistic infections, molecular genetics. Salary negotiable.

American; Avail.5/94.

cloning, DNA sequencing, assay cells, Western blots.

Prefer Ph.D., Ph.D., development, position.


1993,

June 1994.


1994.


1994.


1994.


1994.

1994.

1994.

1994.

1994.

1994.


1994.

1994.

1990. Seeking position in a cancer-related area.


1995.

1994.

1994.


1994.


1994.

1994.

1994.

1994.

1994.

1994.

1994.

1994.

1994.

1994.

1994.

1994.

1994.

1994.

1994.

1994.

1994.

1994.
<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sidransky, D.</td>
<td>3588</td>
</tr>
<tr>
<td>Slattery, J. T.</td>
<td>3436</td>
</tr>
<tr>
<td>Smith, J. D.</td>
<td>3346</td>
</tr>
<tr>
<td>Smith, J. M.</td>
<td>3413</td>
</tr>
<tr>
<td>Sommers, C. L.</td>
<td>3544</td>
</tr>
<tr>
<td>Sporn, M. B.</td>
<td>3413</td>
</tr>
<tr>
<td>Sreekantaiah, C.</td>
<td>3398</td>
</tr>
<tr>
<td>Stewart, J.</td>
<td>3602</td>
</tr>
<tr>
<td>Sugita, K.</td>
<td>3611</td>
</tr>
<tr>
<td>Tagawa, M.</td>
<td>3602</td>
</tr>
<tr>
<td>Taguchi, J.</td>
<td>3407</td>
</tr>
<tr>
<td>Tahara, E.</td>
<td>3373</td>
</tr>
<tr>
<td>Takahashi, S.</td>
<td>3574</td>
</tr>
<tr>
<td>Takao, S.</td>
<td>3620</td>
</tr>
<tr>
<td>Takuwa, N.</td>
<td>3407</td>
</tr>
<tr>
<td>Takuwa, Y.</td>
<td>3407</td>
</tr>
<tr>
<td>Tanaka, H.</td>
<td>3611</td>
</tr>
<tr>
<td>ten Kate, J.</td>
<td>3376</td>
</tr>
<tr>
<td>Thomas, S.</td>
<td>3588</td>
</tr>
<tr>
<td>Thompson, J. A.</td>
<td>3436</td>
</tr>
<tr>
<td>Tolley, R.</td>
<td>3602</td>
</tr>
<tr>
<td>Tomar, R.</td>
<td>3533</td>
</tr>
<tr>
<td>Tomonaga, M.</td>
<td>3329</td>
</tr>
<tr>
<td>Toyama, K.</td>
<td>3557</td>
</tr>
<tr>
<td>Trent, D. F.</td>
<td>3346</td>
</tr>
<tr>
<td>Utiyama, H.</td>
<td>3561</td>
</tr>
<tr>
<td>Vainio, H.</td>
<td>3625</td>
</tr>
<tr>
<td>van Boeckel, C. A. A.</td>
<td>3479</td>
</tr>
<tr>
<td>van den Herik-Oudijk, I. E.</td>
<td>3527</td>
</tr>
<tr>
<td>van de Winkel, J. G. J.</td>
<td>3527</td>
</tr>
<tr>
<td>van Doornmalen, A. M.</td>
<td>3479</td>
</tr>
<tr>
<td>van Driel, M.</td>
<td>3376</td>
</tr>
<tr>
<td>van Oosterhout, Y. V. J. M.</td>
<td>3527</td>
</tr>
<tr>
<td>Varesco, L.</td>
<td>3553</td>
</tr>
<tr>
<td>Vezzon, D.</td>
<td>3365</td>
</tr>
<tr>
<td>von Minckwitz, G.</td>
<td>3337</td>
</tr>
<tr>
<td>Wang, B.</td>
<td>3540</td>
</tr>
<tr>
<td>Wang, Z. Y.</td>
<td>3428</td>
</tr>
<tr>
<td>Waser, B.</td>
<td>3455</td>
</tr>
<tr>
<td>Webber, K. O.</td>
<td>3460</td>
</tr>
<tr>
<td>Wessels, H. M. C.</td>
<td>3527</td>
</tr>
<tr>
<td>Westin, P.</td>
<td>3594</td>
</tr>
<tr>
<td>White, R. L.</td>
<td>3553</td>
</tr>
<tr>
<td>Wiley, J. E.</td>
<td>3357</td>
</tr>
<tr>
<td>Wink, D. A.</td>
<td>3365</td>
</tr>
<tr>
<td>Xie, J.-G.</td>
<td>3428</td>
</tr>
<tr>
<td>Xu, X-C.</td>
<td>3580</td>
</tr>
<tr>
<td>van Driel, M.</td>
<td>3376</td>
</tr>
<tr>
<td>van Oosterhout, Y. V. J. M.</td>
<td>3527</td>
</tr>
<tr>
<td>Varesco, L.</td>
<td>3553</td>
</tr>
<tr>
<td>Vezzon, D.</td>
<td>3365</td>
</tr>
<tr>
<td>von Minckwitz, G.</td>
<td>3337</td>
</tr>
<tr>
<td>Wang, B.</td>
<td>3540</td>
</tr>
<tr>
<td>Wang, Z. Y.</td>
<td>3428</td>
</tr>
<tr>
<td>Waser, B.</td>
<td>3455</td>
</tr>
<tr>
<td>Webber, K. O.</td>
<td>3460</td>
</tr>
<tr>
<td>Wessels, H. M. C.</td>
<td>3527</td>
</tr>
<tr>
<td>Westin, P.</td>
<td>3594</td>
</tr>
<tr>
<td>White, R. L.</td>
<td>3553</td>
</tr>
<tr>
<td>Wiley, J. E.</td>
<td>3357</td>
</tr>
<tr>
<td>Wink, D. A.</td>
<td>3365</td>
</tr>
<tr>
<td>Xie, J.-G.</td>
<td>3428</td>
</tr>
<tr>
<td>Xu, X-C.</td>
<td>3580</td>
</tr>
<tr>
<td>van Driel, M.</td>
<td>3376</td>
</tr>
<tr>
<td>van Oosterhout, Y. V. J. M.</td>
<td>3527</td>
</tr>
<tr>
<td>Varesco, L.</td>
<td>3553</td>
</tr>
<tr>
<td>Vezzon, D.</td>
<td>3365</td>
</tr>
<tr>
<td>von Minckwitz, G.</td>
<td>3337</td>
</tr>
<tr>
<td>Wang, B.</td>
<td>3540</td>
</tr>
<tr>
<td>Wang, Z. Y.</td>
<td>3428</td>
</tr>
<tr>
<td>Waser, B.</td>
<td>3455</td>
</tr>
<tr>
<td>Webber, K. O.</td>
<td>3460</td>
</tr>
<tr>
<td>Wessels, H. M. C.</td>
<td>3527</td>
</tr>
<tr>
<td>Westin, P.</td>
<td>3594</td>
</tr>
<tr>
<td>White, R. L.</td>
<td>3553</td>
</tr>
<tr>
<td>Wiley, J. E.</td>
<td>3357</td>
</tr>
<tr>
<td>Wink, D. A.</td>
<td>3365</td>
</tr>
<tr>
<td>Xie, J.-G.</td>
<td>3428</td>
</tr>
<tr>
<td>Xu, X-C.</td>
<td>3580</td>
</tr>
<tr>
<td>van Driel, M.</td>
<td>3376</td>
</tr>
<tr>
<td>van Oosterhout, Y. V. J. M.</td>
<td>3527</td>
</tr>
<tr>
<td>Varesco, L.</td>
<td>3553</td>
</tr>
<tr>
<td>Vezzon, D.</td>
<td>3365</td>
</tr>
<tr>
<td>von Minckwitz, G.</td>
<td>3337</td>
</tr>
<tr>
<td>Wang, B.</td>
<td>3540</td>
</tr>
<tr>
<td>Wang, Z. Y.</td>
<td>3428</td>
</tr>
<tr>
<td>Waser, B.</td>
<td>3455</td>
</tr>
<tr>
<td>Webber, K. O.</td>
<td>3460</td>
</tr>
<tr>
<td>Wessels, H. M. C.</td>
<td>3527</td>
</tr>
<tr>
<td>Westin, P.</td>
<td>3594</td>
</tr>
<tr>
<td>White, R. L.</td>
<td>3553</td>
</tr>
<tr>
<td>Wiley, J. E.</td>
<td>3357</td>
</tr>
<tr>
<td>Wink, D. A.</td>
<td>3365</td>
</tr>
<tr>
<td>Xie, J.-G.</td>
<td>3428</td>
</tr>
<tr>
<td>Xu, X-C.</td>
<td>3580</td>
</tr>
<tr>
<td>van Driel, M.</td>
<td>3376</td>
</tr>
<tr>
<td>van Oosterhout, Y. V. J. M.</td>
<td>3527</td>
</tr>
<tr>
<td>Varesco, L.</td>
<td>3553</td>
</tr>
<tr>
<td>Vezzon, D.</td>
<td>3365</td>
</tr>
<tr>
<td>von Minckwitz, G.</td>
<td>3337</td>
</tr>
<tr>
<td>Wang, B.</td>
<td>3540</td>
</tr>
<tr>
<td>Wang, Z. Y.</td>
<td>3428</td>
</tr>
<tr>
<td>Waser, B.</td>
<td>3455</td>
</tr>
<tr>
<td>Webber, K. O.</td>
<td>3460</td>
</tr>
<tr>
<td>Wessels, H. M. C.</td>
<td>3527</td>
</tr>
<tr>
<td>Westin, P.</td>
<td>3594</td>
</tr>
<tr>
<td>White, R. L.</td>
<td>3553</td>
</tr>
<tr>
<td>Wiley, J. E.</td>
<td>3357</td>
</tr>
<tr>
<td>Wink, D. A.</td>
<td>3365</td>
</tr>
<tr>
<td>Xie, J.-G.</td>
<td>3428</td>
</tr>
<tr>
<td>Xu, X-C.</td>
<td>3580</td>
</tr>
</tbody>
</table>

3643
AMERICAN ASSOCIATION FOR CANCER RESEARCH
GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:

1. subscriptions to all of the Association's high-quality journals, Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention, at reduced member rates;
2. the privilege of sponsoring a paper for presentation at the AACR annual meeting;
3. an advance copy of the scientific Program and the Proceedings of the American Association for Cancer Research for each annual meeting;
4. reduced registration rates at all scientific meetings;
5. priority notification of events in the AACR's outstanding series of special conferences on timely subjects in the field;
6. the receipt of AACR newsletters, meeting announcements, and an up-to-date membership directory;
7. reduced rates for the AACR Employment Register; and
8. the professional benefits of AACR's public education activities.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate is working in a research area not directly related to cancer but has conducted research of merit in a related area of biomedical science, he or she may also qualify for membership.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status at a later date upon leaving the Americas. Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications should apply for associate membership.

PROCEDURES FOR APPLICATION

There are three deadlines for receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application in AACR Office</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. —OR— The nominator may supply the responses requested at the bottom of the application form in the section entitled 'STATEMENT OF SUPPORT' (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). —OR— The seconder may supply the responses requested at the bottom of the application form in the section entitled 'STATEMENT OF SUPPORT' (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street
Suite 816
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215-440-9313

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues, a major portion of which is designated for subscriptions to AACR publications. In 1994 dues for active members are $150, $95 of which is designated for journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues ($85 in 1994) and may, if they wish, subscribe to Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year's dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti
Executive Director
APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE: ____________________________ DATE OF BIRTH: ____________

LAST FIRST M.I.

PRESENT POSITION/TITLE: ____________________________________________

INSTITUTIONAL AFFILIATION: _______________________________________

INSTITUTIONAL ADDRESS: ___________________________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: ____________________________ FAX NUMBER: ____________

E-MAIL NUMBER (CARRIER): ____________________________

PRIMARY FIELD OF RESEARCH (Please check only one):

____ Biochemistry and Biophysics  ____ Biostatistics  ____ Carcinogenesis

____ Cellular Biology and Genetics  ____ Clinical Investigations  ____ Endocrinology

____ Epidemiology  ____ Immunology  ____ Molecular Biology and Genetics

____ Preclinical Pharmacology and Experimental Therapeutics  ____ Virology

____ Other: ____________________________ (Please specify)

ACADEMIC DEGREES (Including where and when granted)

____________________________________________________________________

____________________________________________________________________

____________________________________________________________________

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

____________________________________________________________________

____________________________________________________________________

____________________________________________________________________

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts.)

____________________________________________________________________

____________________________________________________________________

____________________________________________________________________

____________________________________________________________________

CANDIDATE NOMINATED BY*: ____________________________ (Please print)

CANDIDATE SECONDED BY*: ____________________________ (Please print)

CANDIDATE IS APPLYING FOR (Check one):  □ ACTIVE  □ CORRESPONDING  MEMBERSHIP

STATEMENT OF SUPPORT (in place of letters of recommendation)

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

How long has the candidate worked in the field of cancer research? ____ years
Will the candidate make a long-term contribution to cancer research? ___Yes ____No
Does the candidate’s research adhere to accepted ethical standards? ___Yes ___No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

Signature of nominator* ____________________________ Date ____________________________

Signature of seconder* ____________________________ Date ____________________________

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.

(This form may be reproduced.)
QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AARC), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AARC enjoy the following benefits:

1. the privilege of sponsoring a paper for presentation at the AARC annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AARC also signs the abstract of the paper in support of the work (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the Proceedings of the American Association for Cancer Research which contains abstracts of all papers being presented at each annual meeting;
3. the privilege of registering for the annual meeting at the low student rate (This rate is otherwise available only to predoctoral students.);
4. preferred access to the AARC Employment Register;
5. optional subscriptions to the Association’s high-quality journals Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
6. priority notification of events in the AARC’s series of special conferences on timely subjects in the field;
7. reduced registration rates at special conferences;
8. the receipt of AARC newsletters, meeting announcements, and an up-to-date membership directory; and
9. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AARC. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year's dues payment must accompany the application. Dues are currently $30 for associate members residing in the Americas and $40 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the $30 or $40 dues payment to:

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street
Suite 816
Philadelphia, PA 19106-3483
215/440-9300

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AARC Board of Directors. Dues for 1993 and 1994 have been set at $30 per year for residents of the Americas and $40 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in October 1993 for the forthcoming annual meeting must have paid dues for 1993. Any newly elected associate members of the AARC who have already purchased subscriptions to Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member's subscription.

Each Fall the AARC will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member's current registrar, dean, or department head, verifying the member's current academic status. The Association's By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1993 may retain associate membership until December 31, 1997. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti
Executive Director
**APPLICATION FOR ASSOCIATE MEMBERSHIP**

<table>
<thead>
<tr>
<th>NAME OF CANDIDATE:</th>
<th>DATE OF BIRTH:</th>
</tr>
</thead>
<tbody>
<tr>
<td>LAST</td>
<td>M.I.</td>
</tr>
<tr>
<td>FIRST</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INSTITUTIONAL AFFILIATION:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>INSTITUTIONAL ADDRESS:</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(City)</th>
<th>(State/Province)</th>
<th>(Country)</th>
<th>(Postal Code)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>TELEPHONE NUMBER:</th>
<th>FAX NUMBER:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PRESENT ACADEMIC STATUS/TITLE (Please check only one):</th>
<th>E-MAIL NUMBER (CARRIER):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graduate Student</td>
<td>Medical Student</td>
</tr>
<tr>
<td>Physician in Training</td>
<td>Postdoctoral Fellow</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRIMARY FIELD OF RESEARCH (Please check only one):</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Biochemistry and Biophysics</td>
<td>Biostatistics</td>
</tr>
<tr>
<td>Cellular Biology and Genetics</td>
<td>Clinical Investigations</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>Immunology</td>
</tr>
<tr>
<td>Preclinical Pharmacology and Experimental Therapeutics</td>
<td>Virology</td>
</tr>
<tr>
<td>Carcinogenesis</td>
<td>Endocrinology</td>
</tr>
<tr>
<td>Molecular Biology and Genetics</td>
<td>Other:</td>
</tr>
<tr>
<td>(Please specify)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>---</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>CANDIDATE NOMINATED BY:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(Please type or print name of AACR active member in good standing.)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SIGNATURES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Signature of Candidate:</th>
<th>Date:</th>
</tr>
</thead>
</table>

| I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true. | |

<table>
<thead>
<tr>
<th>Signature of Nominator*:</th>
<th>Date:</th>
</tr>
</thead>
</table>

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year's dues. Dues are currently $30 for associate members residing in the Americas and $40 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:
The enclosed dues payment should be applied to the ☐ current ☐ forthcoming calendar year.

(NO: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in May of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced.)
Guidelines for Submitting Disks
to
American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

- XyWrite III Plus (for the IBM)  
- WordPerfect 4.2, 5.0, 5.1 (for the IBM)  
- WordPerfect (for the Mac)  
- Wordstar (for the IBM)  
- Microsoft Word (for the IBM)  
- Microsoft Word Macintosh (Versions 1–4)  
- Wang OIS (WPS)

Also acceptable:

- Apple II DOS 3.3  
- Apple with Appleworks Software  
- Apple III Plus DOS 3.3  
- Apple Macintosh 400K Disc/ MacWrite 2.2 (text)  
- Apple Macintosh Plus 800K Disc/ MacWrite 4.5 (text)  
- CPT 8000  
- DEC WPS-8  
- DEC Decmate II  
- DEC Decmate III  
- Display Write 3  
- Display Write 4  
- IBM Displaywriter Word Processor 6580  
- Lanier Business One Step  
- Lanier No Problem  
- Lanier Super No Problem  
- MASS-11 PC  
- Multimate  
- PC Write  
- PFS Professional Write  
- Volkswriter 4.0

New releases of word processing software are not always immediately available for conversion. In addition, because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author’s name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: __________________________________________
Name of computer used (e.g., IBM/PS2): _______________________________________
Operating system and version (e.g., DOS 3.3): _________________________________
Word processing program and version (e.g., WordPerfect 5.0): ___________________
    [See reverse for acceptable programs.]

Manuscript number: _________________________________________________________
First author: ________________________________________________________________
Corresponding author (if different from first author): ____________________________
Telephone/FAX numbers: ____________________________________________________

This form (both sides) may be reproduced.
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Transcriptional Control of Cell Growth and Differentiation

Supported by a Generous Grant from the National Institute of Environmental Health Sciences

October 16-20, 1994
Chatham Bars Inn, Chatham (Cape Cod), Massachusetts

CONFERENCE CHAIRPERSONS
Eric N. Olson / Houston, TX
Bruce M. Spiegelman / Boston, MA

PROGRAM COMMITTEE
Elaine V. Fuchs / Chicago, IL
Joan V. Ruderman / Boston, MA

SCIENTIFIC PROGRAM

Opening Lectures
David Baltimore / New York, NY
Robert Tjian / Berkeley, CA
James E. Darnell, Jr. / New York, NY

Cell Cycle and Transcription - I
David M. Livingston / Boston, MA
Stephen J. Elledge / Houston, TX
Robert H. Eisenman / Seattle, WA
Carol L. Prives / New York, NY

Cell Cycle and Transcription - II
George F. Vande Woude / Frederick, MD
Marc Kirschner / Boston, MA
Steven I. Reed / La Jolla, CA

Signal Transduction Systems Influencing Transcription
Joan V. Ruderman / Boston, MA
Marc Montminy / La Jolla, CA
Jean Y. J. Wang / La Jolla, CA
Spyridon Aravantinos-Tsalakonas / New Haven, CT

Transcription Factors Controlling Cell Growth
Michael Karin / La Jolla, CA
Richard Treisman / London, England
Michael Z. Gillman / Cold Spring Harbor, NY

Transcription Factors Controlling Cell Differentiation - I
Bruce M. Spiegelman / Boston, MA
Elaine V. Fuchs / Chicago, IL
Michael G. Rosenfeld / La Jolla, CA
Michael Levine / La Jolla, CA

Transcription Factors Controlling Cell Differentiation - II
Eric N. Olson / Houston, TX
Stuart Orkin / Boston, MA
Charles P. Emerson / Philadelphia, PA

Development
Eddy M. De Robertis / Los Angeles, CA
Richard Behringer / Houston, TX
Janet Rossant / Toronto, Ontario, Canada
Clifford Tabin / Boston, MA

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
(215) 440-9300 (215) 440-9313 (FAX)
MECHANISM OF ACTION OF RETINOIDS, VITAMIN D, AND STEROID HORMONES

An AACR Special Conference in Cancer Research

January 14-19, 1995
Whistler Resort and Conference Centre
Whistler, British Columbia, Canada

CONFEREE CHAIRPERSONS
Michael B. Sporn / Bethesda, MD
Ronald M. Evans / La Jolla, CA
David J. Mangelsdorf / Dallas, TX

PROGRAM COMMITTEE
Vincent Giguere / Toronto, Ontario, Canada
John Wesley Pike / La Jolla, CA

SCIENTIFIC PROGRAM

Special Lectures
Pierre Chambon / Strasbourg, France
Ronald M. Evans / La Jolla, CA

Heterodimerization and Protein/Protein Interactions
Hendrik G. Stunnenberg / Heidelberg, Germany
Bjorn Vennstrom / Stockholm, Sweden
Magnus Pflahi / La Jolla, CA
Christopher K. Glass / San Diego, CA

Receptor Structure
Peter E. Wright / La Jolla, CA

Embyronic Development
Gregor Elchele / Houston, TX
Lee Ann Niswander / New York, NY
Carl Thummel / Salt Lake City, UT
Jeremy Brookes / London, England

Actions of Retinoids
Richard Heyman / La Jolla, CA
Arthur Levin / Nutley, NJ
Jochen Buck / New York, NY
Michael B. Sporn / Bethesda, MD
Lorraine J. Gudas / New York, NY

Analysis of Disease
Benjamin G. Neel / Boston, MA
Kenneth Korach / Research Triangle Park, NC
Hughes de Thé / Paris, France
Günter Schütz / Heidelberg, Germany

Orphan Receptors
David J. Mangelsdorf / Dallas, TX
Vincent Giguere / Toronto, Ontario, Canada
Keith Parker / Durham, NC
Jan-Ake Gustafsson / Huddinge, Sweden

Steroid Hormones
Bert W. O'Malley / Houston, TX
Donald P. McDonnell / Durham, NC
Benita S. Katzenellenbogen / Urbana, IL

Vitamin D
John Wesley Pike / La Jolla, CA
Leonard P. Freedman / New York, NY

Applicants are encouraged to submit abstracts for poster presentation.

Application Deadline: November 3, 1994

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
INSTRUCTIONS FOR AUTHORS

Clinical Cancer Research

SCOPE
Clinical Cancer Research, a new journal of the American Association for Cancer Research, will publish original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer, research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

EDITORIAL POLICY
When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, and Associate Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication.

REVIEW PROCESS
The review process, expedited by fax transmission and overnight mail service, is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

MANUSCRIPT SUBMISSION
Send manuscripts to John Mendelsohn, M.D., Editor-in-Chief. Submit four original sets (not photocopies) of figures along with four copies of the manuscript. One set of figures will be returned to the author if the paper is not accepted for publication. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission.

Rapid communication will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for rapid communication should be included in the letter of submission. Minireviews and Forum articles that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

The letter of submission should suggest the Associate Editor (or Editor-in-Chief) who will serve as primary reviewer of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of up to five potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

FORMAT
Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;

2. A running title of fewer than 50 characters;

3. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;

4. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;

5. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;

6. Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;

7. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;

8. Figures.

REFERENCES
Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission.

SAMPLE REFERENCES:


FIGURES
Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author’s name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity.

Authors are encouraged to submit color figures. The expense of reproducing color photographs will be charged to the author. Submit color figures on flexible backing.

FOR MORE INFORMATION, CONTACT:
John Mendelsohn, M.D., Editor-in-Chief
Clinical Cancer Research
Department of Medicine, Memorial Sloan-Kettering Cancer Center
1275 York Avenue, New York, New York 10021
Telephone 212-639-5878, Fax 212-772-8375.
Call for Papers...
Instructions for Authors on reverse side.

Clinical Cancer Research
An Official Journal of the American Association for Cancer Research
An exciting new forum for clinical and translational cancer research

EDITOR-IN-CHIEF
John Mendelsohn

ASSOCIATE EDITORS
David S. Alberts
Joseph R. Bertino
Clara D. Bloomfield
George J. Bosl
Patricia Donahoe
Isaiah J. Fidler
Stephen H. Friend
Philip D. Greenberg
Daniel C. Ihde
Marc E. Lippman
Michael T. Lotze
John D. Minna
Richard J. O'Reilly
Ira Pastan
Herbert M. Pinedo
Jerome Ritz
Paul Sondel
Michael B. Sporn
Louise C. Strong
Daniel D. Von Hoff
Ralph R. Weichselbaum

SCOPE
Clinical Cancer Research, a new journal of the American Association for Cancer Research, will publish original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

CALL FOR PAPERS
The Editors welcome the submission of manuscripts for their consideration. Authors should follow the format given in the "Instructions for Authors" on the reverse side.
Submit manuscripts to:
John Mendelsohn, M.D., Editor-in-Chief
Clinical Cancer Research
Department of Medicine
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, New York 10021
Telephone 212-639-5878
Fax 212-772-8375

REPRESENTATIVE AREAS OF INTEREST INCLUDE

- Molecular pharmacology and chemotherapy
- Drug sensitivity and resistance
- Tumor immunology and immunotherapy
- Radiobiology and radiation oncology
- Solid tumor oncology
- Hematological malignancies
- Surgical oncology
- Pediatric oncology
- Molecular oncology and cancer genes
- Pathology, markers, and prognostic indicators
- Growth factors, cytokines and signal transduction
- Bone marrow transplantation
- Gene therapy
- Cancer endocrinology
- Cell adhesion, invasion, and metastasis
- Prevention of primary and recurrent cancer
- Differentiation and cell death
- Clinical genetics
- Detection of minimal disease

Clinical Cancer Research will be of interest to professionals in all areas of clinical cancer investigation, including medical and hematological oncology, radiation oncology, pediatric oncology, surgical oncology, pathology, radiology, and clinical genetics.

New in 1995